On February 9, 2021, the US Food and Drug Administration approved the COVID-19 monoclonal antibodies (mAbs) treatment, bamlanivimab (bam-la-niv-i-mab) and etesevimab (e-te-sev-i-mab), that is administered together as a single treatment to prevent severe illness in those infected with COVID-19.
As of January 24, 2022, the U.S. Food and Drug Administration has revoked approval of the COVID-19 monoclonal antibody (mAb) treatment called bamlanivimab and etesevimab in all U.S. states and territories. This is due to an increase in COVID-19 cases caused by the Omicron variant and data showing that REGEN-COV is unlikely to be as effective against it.
Like many other viruses, COVID-19 is evolving and changing over time. This means that what made the virus susceptible to certain treatments or vaccines may change. As COVID-19 becomes an endemic disease, meaning that it is still present but not causing significant disruption in our daily lives, the virus will continue to change and new variants will arise.
In the future, new variants may arise that may once again be treatable with bamlanivimab and etesevimab.
